Form 4: CEO Alstodt Boosts Stake in BioRestorative Therapies
Insider Transaction Report
BioRestorative Therapies' President, CEO, and COB, Lance Alstodt, acquired 15,625 common shares and 11,719 warrants.
Summary
- Lance Alstodt, President, CEO, and Chairman of the Board of BioRestorative Therapies, Inc. (BRTX), acquired additional securities.
- On October 6, 2025, Alstodt acquired 15,625 shares of common stock at a price of $1.6 per share.
- Following this transaction, Alstodt directly beneficially owns 187,497 shares of common stock.
- Additionally, on October 6, 2025, Alstodt acquired 11,719 warrants with an exercise price of $2.75 per share.
- These warrants are exercisable from April 8, 2026, and expire on October 8, 2030.
- Alstodt also holds various stock options: 293,479 shares at $5.08 (expiring 08/18/2031), 42,059 shares at $5.08 (expiring 11/04/2031), 106,762 shares at $2.91 (vesting through 02/17/2023 and quarterly thereafter), 438,596 shares at $1.45 (vesting through 02/13/2024 and quarterly thereafter), and 791,885 shares at $2.46 (vesting through 02/14/2025 and quarterly thereafter).
Sentiment
Score: 8
Explanation: The acquisition of common stock and warrants by the President, CEO, and Chairman of the Board is a strong positive signal, indicating significant insider confidence in the company's future.
Positives
- The President, CEO, and Chairman of the Board, Lance Alstodt, increased his direct beneficial ownership in the company by acquiring common stock and warrants, signaling confidence in the company's future prospects.
- The acquisition of 15,625 common shares at $1.6 per share demonstrates a direct investment by a key insider.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future performance, but rather reports an insider transaction.
Industry Context
This filing, an insider transaction report, does not provide direct information on broader industry trends or competitors. However, insider buying by a CEO can be interpreted as a positive signal regarding the company's future within its industry.
Related Party Transactions
- The reported transactions involve the acquisition of common stock and warrants by Lance Alstodt, who is the President, CEO, Chairman of the Board, and a 10% owner of BioRestorative Therapies, Inc., making these related party transactions.
Stakeholder Impact
- Shareholders may view the CEO's increased stake as a positive indicator of management's belief in the company's value and future performance, potentially boosting investor confidence.
- The transactions could signal stability and a long-term commitment from top leadership.
Key Dates
| Date | Description |
|---|---|
| 08/18/2031 | Expiration date for 293,479 stock options with an exercise price of $5.08. |
| 11/04/2031 | Expiration date for 42,059 stock options with an exercise price of $5.08. |
| 02/17/2023 | Vesting date for 53,381 shares of stock options with an exercise price of $2.91. |
| 02/17/2024 | Start of eight nearly equal quarterly installments for vesting of 53,381 shares of stock options with an exercise price of $2.91. |
| 02/13/2024 | Vesting date for 219,298 shares of stock options with an exercise price of $1.45. |
| 02/13/2025 | Start of eight nearly equal quarterly installments for vesting of 219,298 shares of stock options with an exercise price of $1.45. |
| 02/14/2025 | Vesting date for 395,943 shares of stock options with an exercise price of $2.46. |
| 10/06/2025 | Date of transaction for the acquisition of common stock and warrants by Lance Alstodt. |
| 10/17/2025 | Date the Form 4 was signed by Lance Alstodt. |
| 02/14/2026 | Start of eight nearly equal quarterly installments for vesting of 395,942 shares of stock options with an exercise price of $2.46. |
| 04/08/2026 | Date warrants acquired on 10/06/2025 become exercisable. |
| 10/08/2030 | Expiration date for warrants acquired on 10/06/2025. |
Recommendation
buyThe significant acquisition of common stock and warrants by the President, CEO, and Chairman of the Board, Lance Alstodt, is a strong bullish signal. Insider buying, especially from a top executive, often indicates a belief that the company's stock is undervalued or that significant positive developments are anticipated. This increased stake suggests strong confidence in BioRestorative Therapies' future prospects, making it a favorable indicator for potential investors.
Keywords
BioRestorative Therapies, BRTX, Insider Trading, Form 4, Stock Acquisition, Warrants, Lance Alstodt, CEO, Director, 10% Owner
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.